Intranasal EVs may slow Alzheimer's disease - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Intranasal EVs may slow Alzheimer's disease

Amniotic cell–derived extracellular vesicles improved cognition while reducing amyloid-beta accumulation and neuroinflammation in experimental models.

  • By

  • Andrea Surnit

  • September 16, 2026

  • 3 min

Share

  • 1

    Extracellular vesicles from human amniotic mesenchymal stromal cells may improve cognitive performance in Alzheimer's disease mouse models.

  • 2

    hAMSC-EVs administered intranasally reduced amyloid-beta levels by 53% in treated mice compared to vehicle-treated mice.

  • 3

    Treatment with hAMSC-EVs resulted in reduced neuroinflammation, evidenced by lower microglial and astrocytic density.

  • 4

    RNA cargo in hAMSC-EVs contributed to their immunomodulatory effects, impacting microglial activation and amyloid-beta uptake.

  • 5

    The study's limitations include a focus on female mice and a small human sample, necessitating further research for clinical efficacy.

Original Source(s)

Intranasal EVs may slow Alzheimer's disease

  • by Andrea Surnit

  • September 16, 2026

Related Content

Language Processing Persists Under Anesthesia

Intraoperative recordings suggested preserved processing of speech and auditory context during unconsciousness.

Medical Oddities: Could multilingualism keep you young?

From multilingual minds to pomegranate hearts, gastric mischief, and swishable tea, science stays delightfully odd.

Can external counterpulsation help early Alzheimer disease?

Researchers compared full‐pressure and low‐pressure external counterpulsation during a 12‐month trial in patients with clinically diagnosed early Alzheimer disease.